Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads by Date

Must reads for theWeek ending December 30, 2018

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

More must reads

Must reads for theWeek ending December 23, 2018

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

More must reads

Must reads for theWeek ending December 16, 2018

JULIET trial update on CAR T in DLBCL, Maziarz RT et al. N Engl J Med. 2018 Dec 1. doi: 10.1056/NEJMoa1804980

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6

More must reads

Must reads for theWeek ending December 2, 2018

Radiation guidelines for proton therapy in mediastinal lymphoma, Dabaja BS et al. Blood. 2018 Oct 18;132(16):1635-46. http://www.bloodjournal.org/content/132/16/1635?sso-checked=true

Protein aids differential diagnosis in CLL, Pizzi M et al. Hum Pathol. 2018 Nov 17. doi: 10.1016/j.humpath.2018.10.038

Long-term data on R-CHOP in follicular lymphoma, Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31

Bortezomib looks promising in WM mutations, Sklavenitis-Pistofidis R et al. Blood. 2018 Oct 26. doi: 10.1182/blood-2018-07-863241

Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21

More must reads

Must reads for theWeek ending November 11, 2018

More must reads

Pages